"Plan sponsors can begin preparing for these reforms now by: [1] Reviewing existing PBM agreements to identify provisions that limit data access, restrict audit rights. or delay reporting; [2] Incorporating transparency and disclosure requirements into future PBM contracts, especially those extending into or beyond 2029; [3] Evaluating fiduciary governance practices to ensure processes are in place for reviewing PBM reports and documenting oversight activities; [4] Assessing internal and external resources needed to analyze prescription drug data and identify cost and utilization trends."  MORE >>